BLA
VIVO

Balter Liquid Alternatives’s Meridian Bioscience Inc VIVO Stock Holding History

Balter Liquid Alternatives’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-37,485
Closed -$590K – 170
2017
Q2 		$590K Buy
+37,485
New +$540K 0.68% 36

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Balter Liquid Alternatives's VIVO Position: Q3 2017 in Review

Balter Liquid Alternatives sold out of Meridian Bioscience Inc (VIVO) in Q3 2017, closing a stake of 37,485 shares — an estimated $590K sold.

Balter Liquid Alternatives first reported a position in VIVO in Q2 2017 and held it in 1 quarter. The position peaked at $590K in Q2 2017. 172 funds tracked by Wall St. Rank hold VIVO as of Q3 2017.

  • Balter Liquid Alternatives reported no remaining Meridian Bioscience Inc position as of Q3 2017 after selling out during the quarter.
  • Balter Liquid Alternatives sold 37,485 Meridian Bioscience Inc shares in Q3 2017, an estimated $590K.
  • Balter Liquid Alternatives first reported a position in Meridian Bioscience Inc in Q2 2017 and held it in 1 quarter.
  • Balter Liquid Alternatives's Meridian Bioscience Inc position peaked at $590K in Q2 2017.
  • 172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2017.

Based on Balter Liquid Alternatives's 13F filing for Q3 2017, filed 16 Oct 2017.